Treatment with agmatine inhibits Cryptosporidium parvum infection in infant mice
Related Experiment Video
Updated: Oct 9, 2026
Modeling Ascending Vaginal Infection, Preterm Birth, and Neonatal Morbidity in Mice
Published on: October 10, 2025
D Moore1, W R Waters, M J Wannemuehler
1Veterinary Medical Research Institute, Iowa State University, Ames 50011, USA.
Abstract:
Cryptosporidium parvum is an intracellular protozoan parasite that causes enteric infection and diarrhea in a wide range of mammalian hosts, including humans and economically important livestock species. There are no effective vaccines or drug treatments available for cryptosporidiosis. Cryptosporidium parvum utilizes a unique metabolic pathway for the synthesis of polyamines, forming agmatine as an intermediary metabolite. We treated infant mice with oral doses of agmatine for 2 days before, the day of, and 5 days following experimental infection with C. parvum. Mice treated with agmatine were significantly less infected with C. parvum than were control mice receiving phosphate-buffered saline. Mice treated with agmatine only on the day of experimental infection with C. parvum were also significantly less infected than were control mice. These data suggest that exogenous agmatine alters the metabolism of C. parvum sufficient to interfere with its ability to colonize the mammalian intestine.
Insights
Agmatine administration significantly reduced Cryptosporidium parvum infection in mice. This suggests exogenous agmatine can interfere with the parasite
Area of Science:
- Parasitology
- Infectious Diseases
- Mammalian Metabolism
Background:
- Cryptosporidium parvum causes enteric infections and diarrhea in humans and livestock.
- No effective vaccines or drug treatments currently exist for cryptosporidiosis.
- C. parvum has a unique polyamine synthesis pathway involving agmatine.
Purpose of the Study:
- To investigate the potential of agmatine as a therapeutic agent against C. parvum infection.
- To determine if exogenous agmatine can reduce C. parvum colonization in a mammalian host.
Main Methods:
- Infant mice were orally administered agmatine.
- Mice were infected experimentally with C. parvum.
- Infection levels were compared between agmatine-treated and control groups.
Main Results:
- Agmatine treatment significantly reduced C. parvum infection levels in mice.
- Treatment efficacy was observed when agmatine was administered before, during, or after infection.
- Control mice received phosphate-buffered saline.
Conclusions:
- Exogenous agmatine alters C. parvum metabolism.
- Agmatine interferes with the parasite's ability to colonize the mammalian intestine.
- Agmatine shows promise as a novel therapeutic strategy for cryptosporidiosis.
